Rivus Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Rivus Pharmaceuticals, Inc. - overview
Established
2019
Location
Charlottesville, VA, US
Primary Industry
Biotechnology
About
Founded in 2019 and based in Virginia, US, Rivus Pharmaceuticals, Inc. operates as a biopharmaceutical company for cardio-metabolic health. In September 2022, Rivus Pharmaceuticals, Inc. raised USD 132 million in series B funding led by new investor RA Capital with participation from other new investors BB Biotech Ventures and Bain Capital Life Sciences.
Returning investors Longitude Capital, Medicxi Ventures, and RxCapital also participated in the round. Rivus Pharmaceuticals, Inc. provides a small molecule therapy, HU6, which is a controlled metabolic accelerator (CMA) that addresses the underlying cause of cardio-metabolic disease by harnessing the body's natural processes to improve cellular metabolism. The company will use the series B funding to further support the clinical advancement of HU6 as a therapy for obesity and cardio-metabolic disorders.
Current Investors
Longitude Capital, Medicxi, RxCapital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.rivuspharma.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.